« Return to News | Clinical Intelligence

Generex publishes study results for type I diabetes

Wednesday, May 4, 2011 01:01 PM

Generex Biotechnology has published results of studies applicable to the early diagnosis, and possibly treatment of type I diabetes. The study, entitled "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type I Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism Research. The article reports on the results of a collaborative study between scientists at the University Campus Bio-Medico in Rome, Italy and scientists at Generex's wholly-owned subsidiary, Antigen Express.

The methodology reported in the publication for identification of autoimmune cells in diabetic patients relies upon the Ii-Key technology developed at Antigen Express. Specifically, attaching the Ii-Key segment to an antigenic peptide designed to activate CD4+ T helper cells increases the potency of the peptide while not altering its specificity.


The study reports that Ii-Key modified peptides from each of these proteins were capable of detecting autoimmune T cells in the blood from patients with type I diabetes but not in the blood from normal individuals. Unmodified peptides showed lower sensitivity in detecting autoimmune T cells that the peptides bound to the Ii-Key.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.